There was no significant difference in the rate of tumor growth for mice receiving CD4+ T cells expressing TCR 1 or TCR 3, however, suggesting that clones with differences in TCR avidity can mediate similar CD40L- and CD8-dependent antitumor functions in vivo. The gene discussed is CD8A; the disease is neoplasm.